[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS director David W. J. McGirr reported equity compensation and an option-related share issuance. On June 24, 2026, he received 2,324 Restricted Stock Units and a stock option for 3,691 shares of common stock with an exercise price of $107.55 per share, both as grants.

On June 23, 2026, he exercised 4,712 Restricted Stock Units, receiving the same number of common shares, increasing his direct common stock holdings to 11,712 shares. The new option and RSU awards generally vest by June 24, 2027 or immediately before the issuer’s 2027 annual stockholder meeting, subject to his continued service.

Insights

Equity Compensation Analyst

Routine director equity grants and RSU exercise with no open‑market trading.

The filing shows compensation-related equity activity for director David McGirr at Rhythm Pharmaceuticals. He received 2,324 RSUs and a stock option covering 3,691 shares at an exercise price of $107.55 per share, plus exercised 4,712 RSUs into common stock.

These are non-cash grants and an option-style exercise, not open-market purchases or sales, so the informational signal is modest. After the exercise he directly holds 11,712 common shares, and the new option expires in 2036. Overall, this looks like standard board compensation and routine RSU vesting mechanics.

Insider Trade Summary

4,712 shares exercised/converted

Mixed 4 txns

Insider MCGIRR DAVID W J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,691	$0.00	--
Grant/Award	Restricted Stock Units	2,324	$0.00	--
Exercise	Restricted Stock Units	4,712	$0.00	--
Exercise	Common Stock	4,712	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 3,691 shares (Direct, null); Restricted Stock Units — 2,324 shares (Direct, null); Common Stock — 11,712 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units are fully vested. The restricted stock units have no expiration date. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:08 PM Accepted by SEC EDGAR 06/25/2026 - 06:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCGIRR DAVID W J

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2026		M		4,712	A	(1)	11,712	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/23/2026		M			4,712	(2)	(2)	Common Stock	4,712	$0	0	D
Stock Option (right to buy)	$107.55	06/24/2026		A		3,691		(3)	06/23/2036	Common Stock	3,691	$0	3,691	D
Restricted Stock Units	(1)	06/24/2026		A		2,324		(4)	(4)	Common Stock	2,324	$0	2,324	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units are fully vested. The restricted stock units have no expiration date.

3. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

4. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for David W.J. McGirr	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)